Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally Bacterial co-infections are correlated with unfavorable outcomes in respiratory viral infections. Despite, microbiological and antibiotic data related to COVID-19 are skimpy, competent use of antibiotics in line with antibiotic stewardship (ABS) principles is guaranteed during the pandemic. Bacterial and fungal co-infections are subtle in COVID-19 patients and are mainly ubiquitous in critically ill patients. In addition, studies are needed to estimate the impact of antimicrobial therapy on therapeutic outcomes in COVID-19 patients to prevent antimicrobial overuse. A novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was consequently identified as the causative pathogen. Ordinarily, respiratory viral infections are a risk factor for bacterial co-infections, which then increase disease austerity and mortality. It has been established that sepsis and ventilator-associated pneumonia are frequently observed complications in COVID-19 patients.

    Related Conference of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

    May 30-31, 2024

    World congress on Immunology and Virology Diseases

    Vienna, Austria
    August 01-02, 2024

    44th Global Summit and Expo on Vaccines & Immunology

    Montreal, Canada
    September 09-10, 2024

    4th International Conference on Vaccine Research

    Madrid, Spain
    November 28-29, 2024

    6th World Congress on Vaccine and Immunology

    Paris, France

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in